The markets advanced during the midday with the Dow gaining 32 points to 14,646 as investors turned their attention to earnings. Nasdaq rose 4 points to 3226.
On the upside
A Seeking Alpha contributor affirmed its Buy rating on Himax Technologies (Nasdaq: HIMX).
Unilife (Nasdaq: UNIS) will supply a pharmaceutical with a customized EZMix dual-chamber syringe.
First Solar (Nasdaq: FSLR) announced a record cadmium-telluride photovoltaic module conversion efficiency of 16.1%.
On the downside
Shares of Delcath Systems (Nasdaq: DCTH) continued falling after the Food and Drug Administration extended the review of the medical device maker’s Melblez liver cancer treatment system.
BioCryst Pharmaceuticals (Nasdaq: BCRX) does not hold patents in China for its injectable flu treatment peramivir.
Starwood Property Trust (NYSE: STWD) priced its public offering of 26.5 million common shares at the discounted price of $27.30 per share.
In the broad market, advancing issues outpaced decliners by a margin of nearly 7 to 5 on the NYSE while decliners edged out advancers by more than 10 to 9 on Nasdaq. The broader S&P 500 index added 2 points to 1565.
